Reid Robison, MD MBA was born in Chicago, but grew up in Toronto, Canada. He completed undergraduate studies in Neuroscience at Brigham Young University, and then went on to medical school at the University of Utah where he obtained both his MD and MBA degrees. After residency training in Psychiatry at the University of Utah, Dr. Robison went on to complete fellowship training in Neurodevelopmental Genetics, followed by a post-doc in Bioinformatics. He currently serves as adjunct faculty at both the University of Utah and Brigham Young University.
Dr. Robison then joined the tenure-track faculty at the University of Utah where he conducted industry-sponsored and investigator initiated trials of new neuropsychiatric medicines, and co-directed a genetics lab. He later went on to co-found three healthcare startups that were all acquired. First came Clinical Methods, a phase I-IV CNS clinical trials site, where Dr. Robison led over $15 million in industry-sponsored studies as Principal Investigator. that was acquired by CRI-Lifetree (and later PRA Healthsciences, NASDAQ: PRAH). Dr. Robison also co-founded Anolix, a healthcare data analytics firm dedicated to answering questions for big pharma using machine learning & big data. He then co-founded Tute Genomics, a personalized medicine software company that raised over $10 million in venture capital from various investment partners including Tencent, Intermountain Healthcare, Peak Ventures and more. As CEO of Tute, Dr. Robison was selected to participate in numerous startup incubators and accelerators such as BoomStartup, Healthbox and StartupHealth. Reid continues to share his vision for personalized medicine whenever he gets the chance, as you can see this in action in his TEDx talk on the Genome Revolution.
Dr. Robison has also been active in humanitarian pursuits and was part of the University of Utah’s Global Health Initiative where he made medical trips to post-quake Haiti, refugee camps along the Thai-Burma border, and rural Ghana. He also founded the Polizzi Clinic, a free mental health clinic based in Salt Lake City, Utah, and served as Psychiatrist for Utah Health & Human Rights (seeing refugees & human trafficking subjects). Dr. Robison setup the Consult-Liaison Service at Intermountain Medical Center, Intermountain’s flagship hospital, providing psych consults to the ER and medical floors, and currently serves as Medical Director at Center for Change, one of the top Eating Disorder treatment centers worldwide.
Dr. Robison has extensive experience with Ketamine, in both research and clinic settings, and with psychedelic-assisted psychotherapy in general. In 2011, he conducted his first research study with Ketamine, and then went on to setup a Ketamine program for treatment-resistant depression at Intermountain’s IV Therapy Center at IMC. Dr. Robison was then selected as Principal Investigator for Utah by J&J/Janssen to run a site for the pivotal IV-ketamine treatment-depression study, leading up to the company’s FDA approval of Spravato (esketamine) via breakthrough therapy designation earlier this year. In 2013, the Intermountain Research & Medical Foundation awarded an investigator-initiated grant to Dr. Robison to further study Ketamine for depressive disorders. Dr. Robison also conducted an IRB-approved study of Ketamine for depression and severe eating disorders at Center for Change. He continues to supervise the ketamine therapy practice at Cedar Psychiatry, and believes in careful but prudent use of Ketamine as a tool for transformation in severe depression, PTSD, OCD, and other mental health conditions.
Dr. Robison is a firm believer that inside every person, no matter where they are in their journey, is an inextinguishable light, with the capability for a full human life. Dr. Robison says, “Not all wounds are visible, and everyone has their unique struggle. Pain is real…but so is hope.”